First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
![]() |
- First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney.
- OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA[2] study which recently completed patient enrollment.
- TLX597-Tx is Telix's next...
Read more: First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer





